Idexx Laboratories, Inc. (IDXX) Tops Q2 EPS by 11c; Boosts FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts IDXX Hot Sheet
Price: $566.93 -0.64%
Financial Fact:
Total revenue: 448.31M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total revenue: 448.31M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Idexx Laboratories, Inc. (NASDAQ: IDXX) reported Q2 EPS of $0.83, $0.11 better than the analyst estimate of $0.72. Revenue for the quarter came in at $317.9 million versus the consensus estimate of $308.58 million.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.68-$2.73, versus prior guidance of $2.66-$2.71 and the consensus of $2.70. Idexx Laboratories, Inc. sees FY2011 revenue of $1.205-$1.215 billion, versus the consensus of $1.21 billion.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.68-$2.73, versus prior guidance of $2.66-$2.71 and the consensus of $2.70. Idexx Laboratories, Inc. sees FY2011 revenue of $1.205-$1.215 billion, versus the consensus of $1.21 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
- Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
